Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR 3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ. Maertens JA, et al. Among authors: giladi m. Lancet. 2016 Feb 20;387(10020):760-9. doi: 10.1016/S0140-6736(15)01159-9. Epub 2015 Dec 10. Lancet. 2016. PMID: 26684607 Clinical Trial.
Isavuconazole for treatment of rare invasive fungal diseases.
Cornely OA, Mullane KM, Ostrosky-Zeichner L, Maher RM, Croos-Dabrera R, Lu Q, Lademacher C, Perfect JR, Oren I, Schmitt-Hoffmann AH, Giladi M, Marty FM, Rahav G. Cornely OA, et al. Among authors: giladi m. Mycoses. 2018 Aug;61(8):518-533. doi: 10.1111/myc.12778. Mycoses. 2018. PMID: 29611246 Clinical Trial.
Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole.
Maertens J, Selleslag D, Heinz WJ, Saulay M, Rahav G, Giladi M, Aoun M, Kovanda L, Kaufhold A, Engelhardt M, Cornely OA, Herbrecht R, Ullmann AJ. Maertens J, et al. Among authors: giladi m. Mycoses. 2018 Nov;61(11):868-876. doi: 10.1111/myc.12831. Epub 2018 Aug 13. Mycoses. 2018. PMID: 30035825 Clinical Trial.
Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection.
Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan M, Wiener-Well Y, Weinberger M, Zimhony O, Chowers M, Weber G, Potasman I, Chazan B, Kassis I, Shalit I, Block C, Keller N, Kontoyiannis DP, Giladi M; Israeli Candidemia Study Group. Ben-Ami R, et al. Among authors: giladi m. Antimicrob Agents Chemother. 2012 May;56(5):2518-23. doi: 10.1128/AAC.05947-11. Epub 2012 Feb 6. Antimicrob Agents Chemother. 2012. PMID: 22314534 Free PMC article.
Distribution of fluconazole-resistant Candida bloodstream isolates among hospitals and inpatient services in Israel.
Ben-Ami R, Rahav G, Elinav H, Kassis I, Shalit I, Gottesman T, Megged O, Weinberger M, Ciobotaro P, Shitrit P, Weber G, Paz A, Miron D, Oren I, Bishara J, Block C, Keller N, Kontoyiannis DP, Giladi M; Israeli Candidaemia Study Group. Ben-Ami R, et al. Among authors: giladi m. Clin Microbiol Infect. 2013 Aug;19(8):752-6. doi: 10.1111/1469-0691.12004. Epub 2012 Sep 25. Clin Microbiol Infect. 2013. PMID: 23005038 Free article.
National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases.
Marchaim D, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G, Karplus R, Lazarovitch T, Braun E, Sprecher H, Lachish T, Wiener-Well Y, Alon D, Chowers M, Ciobotaro P, Bardenstein R, Paz A, Potasman I, Giladi M, Schechner V, Schwaber MJ, Klarfeld-Lidji S, Carmeli Y. Marchaim D, et al. Among authors: giladi m. Antimicrob Agents Chemother. 2010 Dec;54(12):5099-104. doi: 10.1128/AAC.00565-10. Epub 2010 Sep 13. Antimicrob Agents Chemother. 2010. PMID: 20837757 Free PMC article.
Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy.
Schechner V, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G, Karplus R, Lazarovitch T, Braun E, Finkelstein R, Lachish T, Wiener-Well Y, Alon D, Chowers M, Bardenstein R, Zimhony O, Paz A, Potasman I, Giladi M, Schwaber MJ, Klarfeld-Lidji S, Hochman M, Marchaim D, Carmeli Y. Schechner V, et al. Among authors: giladi m. Diagn Microbiol Infect Dis. 2011 Sep;71(1):38-45. doi: 10.1016/j.diagmicrobio.2011.05.010. Epub 2011 Jul 16. Diagn Microbiol Infect Dis. 2011. PMID: 21763093
Asking the right question.
Schattner A, Zimhony O, Avidor B, Giladi M. Schattner A, et al. Among authors: giladi m. Lancet. 2003 May 24;361(9371):1786. doi: 10.1016/S0140-6736(03)13415-0. Lancet. 2003. PMID: 12781538 No abstract available.
Cat Scratch Disease Presenting as Fever of Unknown Origin Is a Unique Clinical Syndrome.
Landes M, Maor Y, Mercer D, Habot-Wilner Z, Bilavsky E, Chazan B, Cohen R, Glikman D, Strahilevitz J, Katzir M, Litachevsky V, Melamed R, Guri A, Shaked H, Perets O, Wiener-Well Y, Stren A, Paul M, Zimhony O, Srugo I, Rahav G, Bishara J, Kuperman AA, Ben-Ami R, Ephros M, Giladi M. Landes M, et al. Among authors: giladi m. Clin Infect Dis. 2020 Dec 31;71(11):2818-2824. doi: 10.1093/cid/ciz1137. Clin Infect Dis. 2020. PMID: 31758684
222 results